Accuray and Lausanne University Hospital Join Forces to Offer Patients Personalized Radiation Therapy Treatments
- Collaboration Increases Patient Access to the CyberKnife® and TomoTherapy® Systems
SUNNYVALE, California, Oct. 31, 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) today announced a long-term collaboration with Lausanne University Hospital, Switzerland covering the CyberKnife® and TomoTherapy® Systems. The alliance is based on a mutual commitment to ongoing research in radiation oncology and the development of innovative treatments that improve the quality of life for cancer patients.
At Lausanne University Hospital, patients will now have access to the newest CyberKnife and TomoTherapy Systems on the market. Healthcare professionals may also gain exposure to both systems through peer-to-peer training and education at the hospital. In addition, the two respected organizations intend to collaborate on clinical development and ongoing product innovations, benefiting both healthcare professionals and their patients.
Further information on the systems is available at:
http://www.accuray.com/solutions/treatment-delivery/cyberknife-treatment-delivery/m6-series
http://www.accuray.com/solutions/treatment-delivery/tomotherapy-treatment-delivery/h-series
"Accuray continuously strives to provide clinicians and their patients with radiation treatment options that deliver superior tumor control and minimal side effects," said Lionel Hadjadjeba, SVP International Business & GM Accuray International. "The collaboration with Lausanne University Hospital will enable us to benefit from a group of extremely experienced and skilled clinicians and physicians, and accelerate clinical and product development opportunities that may enhance quality of care."
Lausanne University Hospital is a renowned academic hospital featuring an advanced oncology department and a strong team of clinicians and medical physicists lead by Prof. Pierre-Francois Leyvraz, General Manager, Lausanne University Hospital, Lausanne, Switzerland. Its technical platform is equipped with, among others, the TomoTherapy H™ Series recently upgraded with VoLO™ and TomoEDGE™, and the CyberKnife M6™ System. The hospital is viewed as a leader in medical care, research and training within the European community. Further information about the hospital is available at: http://www.chuv.ch/radio-oncologie/rth_home/rth-patients-et-familles/rth-patients-radiotherapie.htm.
"We view Accuray as a 'partner of choice' and believe our collaboration will further our mission to pioneer medical advances in the field of radiation oncology that are recognized by clinicians around the world," said Prof. Pierre-Francois Leyvraz, General Manager, Lausanne University Hospital, Lausanne, Switzerland. "We're pleased with the agreement because it provides us with the opportunity to have a meaningful impact on the next generation of radiation oncology treatments."
About the CyberKnife® and TomoTherapy® Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the expected benefits and results of Accuray's relationship with Lausanne University Hospital, including but not limited to clinical and product development opportunities, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 29, 2014, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
RELATED LINKS
http://www.accuray.com
Share this article